Full-Time

Vice President

Molecular Profiling Computational Data Sciences

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$300k - $500k/yr

Expert

Tarrytown, NY, USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Data Science
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Regeneron Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Both deep and broad expertise in the field of computational biology and quantitative sciences.
  • Experience in bioinformatic processing of Cas9 and other genetic screens.
  • Ability to aid in promoter design for gene therapy.
  • Familiarity with cutting edge technologies and next generation sequencing platforms with a proven experience of applying technologies to biomedical research related questions essential.
  • Strong written and oral communication skills with the ability to communicate both science and vision essential.
  • Strong leadership skills with managerial and mentorship experience and excellence essential.
  • Experience with administratively directing a large group (managing budget and organization, etc.) is essential.
Responsibilities
  • Directly supervise Regeneron’s senior Molecular profiling Data science team and manage the broader group, providing vision, inspiration, and both short-term and long-term goals.
  • Identify new strategies, computational tools or technologies, including genetic medicines and gene therapies, for pursuing novel targets and approaches.
  • Set priorities and ensure progression of, or go/no-go decisions for, research targets and projects within the Data Sciences Group.
  • Actively participate in departmental, cross-functional, senior leadership, and external meetings to contribute genomic expertise and to represent the goals and vision of the Data Sciences group.
  • Work collaboratively with the Research IT group to develop and populate interfaces to allow non-bioinformatician scientists to easily and intuitively query large public and proprietary RNAseq and other omits datasets to enable target discovery and the development of targeted therapies.
  • Interact broadly and collaboratively with other therapeutic focus areas and technology groups within the company, forging relationships and active collaborations, as well as leveraging technologies to advancing our research portfolio.
  • Lead and mentor the Molecular Profiling Data Sciences Group, providing opportunities, visibility, and challenge in order to develop all group members to their maximum scientific and professional potential.
  • Conduct or oversee review of genomic-related documents, including regulatory submissions, manuscripts, contracts, etc.
  • Interact collaboratively with peer colleagues in the Regeneron Genetics Center and Corporate IT.
Desired Qualifications
  • Expertise in the selection of lead templates from various gene therapy modalities (siRNA, shRNA) and delivery systems (viral and non-viral) would be desirable.
  • Exposure to drug development or similar regulated activities highly desirable.
  • Broad network of colleagues and collaborators, strong publication record, and national/international reputation is desirable.
  • At least 10 years’ experience after PhD; 20+ years desirable; a minimum of 8 years in an industry or translational setting.
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and licensing its technologies. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring they meet safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent's approval for CSU opens a new market segment in the US.
  • $3.6 billion Tarrytown expansion boosts research capabilities and local economy.
  • Partnership with Fujifilm enhances manufacturing capacity for biologics.

What critics are saying

  • Tarrytown expansion poses financial risk if ROI is not realized.
  • Dependency on Fujifilm for manufacturing may lead to operational risks.
  • Regulatory setbacks, like Dupixent's initial rejection, can impact market entry.

What makes Regeneron Pharmaceuticals unique

  • Regeneron specializes in life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug development.
  • Regeneron collaborates with academic and research institutions to enhance R&D efforts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

Ophthalmology Times
Apr 28th, 2025
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR

Regeneron has announced the upcoming presentation of 27 abstracts, including 8 oral presentations on aflibercept injection 8 mg (EYLEA HD) in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Pharma Journalist
Apr 24th, 2025
Regeneron Invests in Expanding Biologic Medicine Manufacturing

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

Texas Border Business
Apr 23rd, 2025
America's Manufacturing Power Surges as Global Giants Invest Billions

Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.

Pharmaceutical Technology
Apr 22nd, 2025
Regeneron partners with Fujifilm to broaden manufacturing capacity

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.